Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

AstraZeneca (Moventig)

AstraZeneca (Moventig)
M&A STATUS
Asset Purch. LATEST DEAL TYPE
1 FINANCING ROUNDS
Description

Drug for opioid-induced constipation (OIC) treatment. The portfolio consists of the rights to sell and develop Moventig (naloxegol) in the European Union (EU), Iceland, Norway, Switzerland and Liechtenstein.

Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Corporate Backed or Acquired
Primary Industry
Pharmaceuticals
Parent Company
Primary Office
  • 2 Kingdom Street
  • London W2 6BD
  • England, United Kingdom

AstraZeneca (Moventig) Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore AstraZeneca (Moventig)‘s full profile, request access.

Request full access to PitchBook

AstraZeneca (Moventig) Former Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore AstraZeneca (Moventig)‘s full profile, request access.

Request full access to PitchBook